Feeds:
Posts
Comments

We’re seeing an acceleration of M&A activity and a growing IPO pipeline through the end of 2016, but the bar remains high.

 

Reporter: Aviva Lev-Ari, PhD, RN

 

Here’s what one top VC firm predicts will happen to tech startups in 2017

Accel is an early & growth-stage venture capital firm and is known for its investments in Facebook, Slack, and Dropbox. This is the firm’s annual presentation on what the tech environment is like for founders today and what will happen in 2017, republished with permission.

  1. It’s an incredible time to be a technology entrepreneur.
  2. A rising “new guard” are officially the most valuable companies in the world: Apple, Alphabet/Google, Microsoft, Amazon, Facebook.
  3. But of course, it’s important to stay disciplined.
  4. We’re seeing an acceleration of M&A activity and a growing IPO pipeline through the end of 2016, but the bar remains high.

 

*In order as of 11/22/16:

  • Apple — $596B
  • Alphabet/Google — $551B
  • Microsoft — $478B
  • Amazon — $372B
  • Facebook — $348B

**Bloomberg dug into the numbers here too.

 

SOURCE

http://www.businessinsider.com/accel-2017-vc-predictions-2016-11


Top Authors for All Days ending 2016-12-01: GROWTH Trends @Leaders in Pharmaceutical Business Intelligence (LPBI) Group

 

Curator: Aviva Lev-Ari, PhD, RN

 

Date |Views to Date |# of articles |NIH Clicks |Nature Clicks

12/1/2016 1,107,643  4,972 3,398  2,279

Be proud to be part of this team !!!

Forthcoming SEVEN e-Books in 2016 AND Eight e-Books on Amazon.com

https://pharmaceuticalintelligence.com/2016/04/24/new-e-book-titles-forthcoming-on-amazon-com-in-2016-from-lpbi-groups-biomed-e-series-forthcoming-cover-pages/

WE ARE ON AMAZON.COM

http://www.amazon.com/dp/B00DINFFYC

http://www.amazon.com/dp/B018Q5MCN8

http://www.amazon.com/dp/B018PNHJ84

http://www.amazon.com/dp/B018DHBUO6

http://www.amazon.com/dp/B013RVYR2K

http://www.amazon.com/dp/B012BB0ZF0

http://www.amazon.com/dp/B019UM909A

http://www.amazon.com/dp/B019VH97LU

 

GROWTH TRENDS: e-Readers, # of articles, NIH Clicks, Nature Clicks

2013, 2014, 2015, 2016

Scientific Journal Site Statistics

Date |Views to Date |# of articles |NIH Clicks |Nature Clicks

07/29/2013   217,356 1,138 1,389 705

12/01/2013   287,645 1,428 1,676 828

02/09/2014   325,039 1,665 1,793 892

03/05/2014   338,958 1,717 1,830 965

03/21/2014   347,667 1,750 1,838 974

03/31/2014  352,683 1,768 1,869 991

05/12/2014  373.696  1,878  1,944  1,035

06/18/2014  393,111  1,992  1,982  1,087

7/27/2014  418,570  2,098  2.050  1,124

9/2/2014  444,222  2,226  2,104  1,170

10/9/2014 471,117  2,337  2,147  1,216

11/4/2014  492,736  2,471  2,194 1,234

2/15/2015  572,027 2,727  2,358  1,345

3/10/2015 591,520 2,808 2,373 1,369

6/7/2015   661,215 3,007 2,562 1,535

7/27/2015 694,298 3,085 2,583 1,572

8/18/2015 709,609  3,173 2,613 1,573

02/18/2016  886,454  4,162   2,911  1,813 

Date |Views to Date |# of articles |NIH Clicks |Nature Clicks

12/1/2016 1,107,643  4,972 3,398  2,279

 

Be proud to be part of this team !!!

 

Top Authors for all days ending 2016-12-01 (Summarized)

Author Views
Aviva Lev-Ari, PhD, RN 295,929
larryhbern 203,736
tildabarliya 43,869
sjwilliamspa 35,934
Dror Nir 23,073
Dr. Sudipta Saha 19,509
ritusaxena 14,934
 
Demet Sag, Ph.D., CRA, GCP 12,025
aviralvatsa 7,942
zraviv06 7,176
zs22 3,738
anamikasarkar 3,182
danutdaagmailcom 2,283
pkandala 2,097
Gail S Thornton 2,035
Alan F. Kaul, PharmD., MS, MBA, FCCP 1,975
Aashir Awan, Phd 1,775
megbaker58 1,408
jdpmd 1,345
Irina Robu 879
Ed Kislauskis 546
howarddonohue 521
evelinacohn 344
David Orchard-Webb, PhD 341
apreconasia 332
stuartlpbi 252
jukkakarjalainen 226
gerag2015 90
kellyperlman 59
Rosalind Codrington, PhD 29
Debashree 22

 

 Top Posts for all days ending 2016-12-03 (Summarized)

 

 All Time  
 
Title
  Views
Home page / Archives 402,487
Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View? – Dr. Larry Bernstein 14,861
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) Aviva Lev-Ari, et al 9,080
Recent comprehensive review on the role of ultrasound in breast cancer management Dr. Dror Nir 6,720
Paclitaxel vs Abraxane (albumin-bound paclitaxel) Tilda Barliya, PhD 5,695
Our TEAM  Aviva Lev-Ari, PhD, RN 5,539
Mesothelin: An early detection biomarker for cancer (By Jack Andraka)

Tilda Barliya, PhD

5,051
Akt inhibition for cancer treatment, where do we stand today?

Ziv Raviv, PhD

3,843
Newer Treatments for Depression: Monoamine, Neurotrophic Factor & Pharmacokinetic Hypotheses – Zohi Sternberg, PhD 3,740
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care – Dr. Justin Pearlman and Aviva Lev-Ari, PhD, RN 3,418
Volume One: Perspectives on Nitric Oxide in Disease Mechanisms

Editors: Dr. Larry Bernstein, Aviral Vatsa, PhD and Stephen J Williams, PhD

3,389
Confined Indolamine 2, 3 dioxygenase (IDO) Controls the Hemeostasis of Immune Responses for Good and Bad – Demet Sag, PhD 3,181
AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo – Stephen J Williams, PhD 3,149
Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications – Aviva Lev-Ari, PhD, RN 3,082
Founder  Aviva Lev-Ari, PhD, RN 3,075
BioMed e-Series – Aviva Lev-Ari, PhD, RN 2,944
The mechanism of action of the drug ‘Acthar’ for Systemic Lupus Erythematosus (SLE) Aviva Lev-Ari, PhD, RN et al 2,728
Introduction to Transdermal Drug Delivery (TDD) system and nanotechnology – Tilda Barliya, PhD 2,728
The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets –  Dr. Larry Bernstein, Dr. Justin Pearlman and Aviva Lev-Ari, PhD, RN 2,715
VISION  Aviva Lev-Ari, PhD, RN 2,527
Alternative Designs for the Human Artificial Heart: Patients in Heart Failure – Outcomes of Transplant (donor)/Implantation (artificial) and Monitoring Technologies for the Transplant/Implant Patient in the Community – Dr. Larry Bernstein, Dr. Justin Pearlman and Aviva Lev-Ari, PhD, RN 2,487
Funding, Deals & Partnerships – Aviva Lev-Ari, PhD, RN 2,436
Biochemistry of the Coagulation Cascade and Platelet Aggregation – Part I

Dr. Larry Bernstein

2,318
FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules –  Stephen J Williams, PhD 2,260
Bone regeneration and nanotechnology –  – Tilda Barliya, PhD 2,252
“The Molecular pathology of Breast Cancer Progression” –  – Tilda Barliya, PhD 2,233
Causes and imaging features of false positives and false negatives on 18F-PET/CT in oncologic imaging – Dror Nir, PhD 2,150
About  Aviva Lev-Ari, PhD, RN 2,036
In focus: Circulating Tumor Cells – Ritu Saxena, PhD 2,034
Mitochondria: Origin from oxygen free environment, role in aerobic glycolysis, metabolic adaptation – Dr. Larry Bernstein 2,016
Treatment Options for Left Ventricular Failure – Temporary Circulatory Support: Intra-aortic balloon pump (IABP) – Impella Recover LD/LP 5.0 and 2.5, Pump Catheters (Non-surgical) vs Bridge Therapy: Percutaneous Left Ventricular Assist Devices (pLVADs) and LVADs (Surgical)

Larry H Bernstein, MD, FCAP and Justin D Pearlman, MD, PhD, FACC

1,983
Journal PharmaceuticalIntelligence.com – Aviva Lev-Ari, PhD, RN 1,977
Pacemakers, Implantable Cardioverter Defibrillators (ICD) and Cardiac Resynchronization Therapy (CRT) – Justin D Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN 1,967
Problems of vegetarianism – Sudipta Saha, PhD 1,903
Sexed Semen and Embryo Selection in Human Reproduction and Fertility Treatment – Sudipta Saha, PhD 1,844
DNA Structure and Oligonucleotides – Larry H Bernstein, MD, FCAP 1,796
Targeting the Wnt Pathway [7.11] – Larry H Bernstein, MD, FCAP 1,759
Biosimilars: CMC Issues and Regulatory Requirements – Aviva Lev-Ari, PhD, RN 1,726
Interaction of enzymes and hormones – Sudipta Saha, PhD 1,716
Nitric Oxide and Platelet Aggregation – Dr. Venkat S. Karra, Ph.D. 1,713
CD47: Target Therapy for Cancer – Tilda Barliya, PhD 1,712
Peroxisome proliferator-activated receptor (PPAR-gamma) Receptors Activation: PPARγ transrepression for Angiogenesis in Cardiovascular Disease and PPARγ transactivation for Treatment of Diabetes –

Aviva Lev-Ari, PhD, RN

1,711
Introduction to Tissue Engineering; Nanotechnology applications

Tilda Barliya, PhD

1,666
Non-small Cell Lung Cancer drugs – where does the Future lie? –

Ritu Saxena, PhD

1,658
Nanotechnology: Detecting and Treating metastatic cancer in the lymph node – Tilda Barliya, PhD 1,583
A Primer on DNA and DNA Replication – Larry H. Bernstein, MD, FCAP 1,572
Lipid Metabolism – Larry H. Bernstein, MD, FCAP 1,568
Outcomes in High Cardiovascular Risk Patients: Prasugrel (Effient) vs. Clopidogrel (Plavix); Aliskiren (Tekturna) added to ACE or added to ARB

Aviva Lev-Ari, PhD, RN

1,532
The SCID Pig: How Pigs are becoming a Great Alternate Model for Cancer Research – Stephen J Williams, PhD 1,489
Biosimilars: Intellectual Property Creation and Protection by Pioneer and by Biosimilar Manufacturers – Aviva Lev-Ari, PhD, RN 1,459

p53 mutation – Li-Fraumeni Syndrome – Likelihood of Genetic or Hereditary conditions playing a role in Intergenerational incidence of Cancer

 

Reporter: Aviva Lev-Ari, PhD, RN

 

THIS ARTICLE IS RECOMMENDED READING TO ALL OUR e-Readers

because it is a REAL story of a high school student fighting Brain Cancer, glioblastoma multiforme (GBM)

it presents the FRONTIER OF GENOMICS, PRECISION MEDICINE, Interventional Radiology and Interventional ONCOLOGY at

Stanford University, Canary Center at Stanford for Early Cancer Detection, Stanford Medical Center and Lucile Packard Children’s Hospital

I was exposed to Li-Fraumeni Syndrome in the following article:

‘And yet, you try’ – A father’s quest to save his son

http://stanmed.stanford.edu/2016fall/milan-gambhirs-li-fraumeni-syndrome.html

 

Li-Fraumeni syndrome

Other Names for This Condition

  • LFS
  • Sarcoma family syndrome of Li and Fraumeni
  • Sarcoma, breast, leukemia, and adrenal gland (SBLA) syndrome
  • SBLA syndrome

LFS is a rare disorder that greatly increases the risk of developing several types of cancer, particularly in children and young adults.

The cancers most often associated with Li-Fraumeni syndrome include breast cancer, a form of bone cancer called osteosarcoma, and cancers of soft tissues (such as muscle) called

Soft tissue sarcoma forms in soft tissues of the body, including muscle, tendons, fat, blood vessels, lymph vessels, nerves, and tissue around joints.


(small hormone-producing glands on top of each kidney). Several other types of cancer also occur more frequently in people with Li-Fraumeni syndrome.

A very similar condition called Li-Fraumeni-like syndrome shares many of the features of classic Li-Fraumeni syndrome. Both conditions significantly increase the chances of developing multiple cancers beginning in childhood; however, the pattern of specific cancers seen in affected family members is different.

Genetic Changes

The CHEK2 and TP53 genes are associated with Li-Fraumeni syndrome.

More than half of all families with Li-Fraumeni syndrome have inherited mutations in the gene. TP53 is a tumor suppressor gene, which means that it normally helps control the growth and division of cells. Mutations in this gene can allow cells to divide in an uncontrolled way and form tumors. Other genetic and environmental factors are also likely to affect the risk of cancer in people with TP53 mutations.

A few families with cancers characteristic of Li-Fraumeni syndrome and Li-Fraumeni-like syndrome do not have TP53 mutations, but have mutations in the CHEK2 gene. Like the TP53 gene, CHEK2 is a tumor suppressor gene. Researchers are uncertain whether CHEK2 mutations actually cause these conditions or are merely associated with an increased risk of certain cancers (including breast cancer).

Inheritance Pattern

Li-Fraumeni syndrome is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to increase the risk of developing cancer. In most cases, an affected person has a parent and other family members with cancers characteristic of the condition.

Diagnosis and Management

These resources address the diagnosis or management of Li-Fraumeni syndrome:

References on LFS

SOURCE

https://ghr.nlm.nih.gov/condition/li-fraumeni-syndrome


LIVE Tweets via @pharma_BI and @AVIVA1950 for Presentations on 11/16 – 11/17, 2016, The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

 

  1. Aviva Lev-Ari‏@AVIVA1950 Nov 17

#PMConf The 12th Annual Personalized Medicine Conference, GENOMICS data sharing initiatives https://pharmaceuticalintelligence.com/2016/11/17/live-1117-145pm-5pm-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/ … via @Pharma_BI

 

  1. Aviva Lev-Ari‏@AVIVA1950 Nov 17

LIVE 11/17 1:45PM – 5PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, … https://pharmaceuticalintelligence.com/2016/11/17/live-1117-145pm-5pm-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/ … via @Pharma_BI

 

  1. Aviva Lev-Ari‏@AVIVA1950 Nov 17

#PMConf @pharma_BI Announcing: BROAD + Intel Center for Advanced Genomic Data Engineering, Anthony Philippakis, M.D., Ph.D.,Broad Institute

 

  1. Aviva Lev-Ari‏@AVIVA1950 Nov 17

#PMConf @pharma_BI My Research Legacy: Broad & AHA – Launched November 13, 2016 Anthony Philippakis, M.D., Ph.D., AMAZING mind among us

 

  1. Aviva Lev-Ari‏@AVIVA1950 Nov 17

3PMConf @pharma_BI Genetic component to become part of Patient care Recepient Leadership in Personalized Medicine Award, Raju Kucherlapati

 

  1. Aviva Lev-Ari‏@AVIVA1950 Nov 17

#PMConf @pharma_BI Kristine Bordenave, M.D., Lead Medical Director, Humana complex Clinical perspective, cost to patient, clinician, Pharma

  1. Aviva Lev-Ari‏@AVIVA1950 Nov 17

#PMConf @pharma_BI 25 of 50 States are participants in MOlDx — NOT New England State Elaine Jeter, M.D., MolDx Medical Director, Palmetto

 

  1. Aviva Lev-Ari‏@AVIVA1950 Nov 17

#PMConf @pharma_BI Richard Hamermesh, Harvard Bus School led GREAT Case Study Presentation on IP disputed DNA-editing technologies, CRISPR

 

9.  Aviva Lev-Ari ‏@AVIVA1950  Nov 17

#PMConf @pharma_BI 65,000 molecular tests in the market in the Registry only 10,000 Elaine Jeter, M.D., MolDx Medical Director, PalmettoGBA

10. Aviva Lev-Ari‏@AVIVA1950 Nov 17

@pharma_BI #PMConf Daniel O’Day, CEO, Roche Pharmaceuticals is Optimistic on Personalized Med – new US Gov’t – no change in Roche Mission

11. Aviva Lev-Ari‏@AVIVA1950  Nov 16

#PMConf Pricing Drugs and THerapeutic Outcomes, The 12th Annual Personalized Medicine Conference, HMS https://pharmaceuticalintelligence.com/2016/11/16/live-1116-315pm-530pm-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/ … via @Pharma_BI

 

 

  1. Aviva Lev-Ari‏@AVIVA1950  Nov 16

#PMConf Molecular DIagnostics LIVE 11/16 1:15PM – 2:45PM – The 12th Annual PM Conference, https://pharmaceuticalintelligence.com/2016/11/16/live-1116-115pm-245pm-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/ … via @Pharma_BI

 

  1. Aviva Lev-Ari‏@AVIVA1950  Nov 16

STAR @ #PMConf Eric Dishman, Director, All of Us Research Program, National Institutes of Health https://pharmaceuticalintelligence.com/2016/11/16/live-1116-8am-noon-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/ … via @Pharma_BI

 

  1. Aviva Lev-Ari‏@AVIVA1950  Nov 16

@pharma_BI @AVIVA1950 #PMConf LIVE Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Jose… https://pharmaceuticalintelligence.com/2016/11/16/live-1116-8am-noon-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/ … via @Pharma_BI

 

  1. Aviva Lev-Ari‏@AVIVA1950  Nov 16

#PMConf @pharma_BI @AVIVA1950 covering in REAL TIME 12th Annual @PartnersPersMed at Harvard Medical School @harvardmed today + tomorrow

 

 

 


Real Time Coverage and eProceedings of Presentations on 11/16 – 11/17, 2016, The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

 

LIVE 11/16 8AM – noon The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

https://pharmaceuticalintelligence.com/2016/11/16/live-1116-8am-noon-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/

 

LIVE 11/16 1:15PM – 2:45PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

https://pharmaceuticalintelligence.com/2016/11/16/live-1116-115pm-245pm-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/

 

LIVE 11/16 3:15PM – 5:30PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

https://pharmaceuticalintelligence.com/2016/11/16/live-1116-315pm-530pm-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/

 

LIVE 11/17 8AM – 1:45PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

https://pharmaceuticalintelligence.com/2016/11/17/live-1117-8am-145pm-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/

 

LIVE 11/17 1:45PM – 5PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

https://pharmaceuticalintelligence.com/2016/11/17/live-1117-145pm-5pm-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/

 


LIVE 11/17 1:45PM – 5PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

 

Leaders in Pharmaceutical Business intelligence (LPBI) Group

Covering in Real Time using Social Media this Event on

Personalized Medicine

Aviva Lev-Ari, PhD, RN, Founder LPBI Group & Editor-in-Chief

http://pharmaceuticalintelligence.com

Streaming LIVE @ HARVARD MEDICAL SCHOOL,

Joseph B. Martin Conference Center

@pharma_BI

@AVIVA1950

November 17

#PMConf

1:45 p.m. — Leadership in Personalized Medicine Award

  • Presenter: William S. Dalton, Ph.D., M.D., CEO, M2Gen, Chairman, Personalized Medicine Coalition

Science, Business and Patents: Millenium, Celgenics, and Medicine/Desease – Member of AAAS

co-Chair Cancer Consorcium

PM – 1990’s on. How Human Genome at Harvard will start a new center – reach out to the Global community, conference was born. PM as subject of a Global Conference, effirt started with Genzyme, Eric Launder, Broad, Collins at NIH – effort led to Obama Initiative in PM, Duke Medical System.

Challenge: Reimbursement for Genomics diagnosis

  • PM – P care – by sequencing of Genome – become available commercially inexpensivelly
  • Genetic component to become part and parcial of Medicine and Patient care

2:15 p.m. — Networking Break

2:45 p.m. — The Data Dilemma: Fulfilling Expectations of Big Data in the Future of Personalized Medicine

There is consensus that the massive amounts of genomic, clinical, claims and other types of data could yield important insights for research and clinical care. But for years, obstacles around technical standards, interoperability, privacy and confidentiality, data security, and consent have been held up as daunting challenges that inevitably slowed progress.  During this discussion, a panel of academic and industry experts will discuss their respective organizations’ strategies to obtain and analyze the data, including what has worked and what has not; the programs and processes that have led to the most productive data usage; examples of important knowledge that has been derived from data analysis; and the infrastructure they believe is needed to achieve fulfillment of the potential of big data in personalized medicine nationwide.

  • Moderator: Marcia A. Kean, M.B.A., Chairman, Strategic Initiatives, Feinstein Kean Healthcare
  1. How one works with 20 Partners at once?

 

  • Paul Bleicher, M.D., Ph.D., CEO, OptumLabs
  1. Data collaboration of 35 Partners – bring value to Medicine, Like Bell Labs
  2. Academics, Hospitals, Physician offices – Constellations – groups of projects
  3. DATA is KEY — Public and Private Partnerships
  • Christophe G. Lambert, Ph.D., Associate Professor, Center for Global Health, Division of Translational Informatics, Department of Internal Medicine, University of New Mexico
  1. VA Data, Co-Chair of Informatics, clinical , pharmaceutical stackholders
  2. Focus Groups Patient research Partners – How to automate data
  3. Centralization above nad decentralization, below COntrol mechanism govern all variables: Increase fitness of system vs Personal Control
  4. 1984-1998 Bi-Partisan support for Data in HealthCare
  5. Big Data for early detection, prevention, `
  6. AGING, Infectious and Pediatric disease – Investment in these areas
  • Adam Margolin, Ph.D., Director, Computational Biology, Oregon Health & Science University School of Medicine
  1. Project with Intel – across institutions
  2. consorsium – success ration
  3. data sharing #1 Priority at the National Level
  4. Add value by data sharing, strategic investment in the healh system
  • Edward J. Stepanski, Ph.D., Chief Operating Officer, Vector Oncology
  1. Propriatory real time reporting to Physicians – systematic – core asset, originally,
  2. Research Group use Warehouse doing Analytics, Tools development linked with clinical data with PRO and studies based on data integretion
  3. Success is more data – PRO data informing clinical data
  4. Defragmenting the care vs drive across town for care several units disaggregated geography vs all deaprtments in one location

 

3:45 p.m. — Keynote Speaker
“Medicine and the Targeted Marketing Problem”

We live in the golden age of cloud computing and machine learning.  The organizing conundrum for the “big data era,” however, is a surprising one — the “targeted marketing problem” (i.e., the ability to better match the right customers to targeted messages). This talk will explore overlaps and similarities between the targeted marketing problem and precision medicine, and how advances in data sciences can be leveraged to create a learning medical system that in turn points to the health care system of the future.

  • Introduction: Amy Abernethy, M.D., Ph.D., Chief Scientific Officer, Senior Vice President, Oncology, Flatiron Health

 

  • Anthony Philippakis, M.D., Ph.D., Cardiologist, BWH, Chief Data Officer, Broad Institute and Partner, GV (Venture Capital)

Learning from Users

Five causes for cardiac death:

  • MI,
  • a-Fib
  • Structural
  • PE
  • Aorta dissection

PreventionGenomic Sequencingvalue in Cardiology:

  • Estonia BioBank – mutation carrier
  • Familial Hypercholesterolemia – 4 genes involved,
  • Prediction sudden cardiac death – larger data sets
  • New Model for Human Subjects Research; DIrect-to-Participant: Potentia Advantages:
  • cost, scalability, facilitate re-contact, frequent collection,
  • My Research Legacy: Broad & AHA – Launched November 13, 2016 
  • Quantified Self –>> Quantigied Physical Exam: Face dysformia, Dysarthia, Ataxia,
  • Identify every patient in the World  with this disease

 

Data sharing: Inverting the Model ; ALL OF US  – 1 Million – Precision Medicine with IBM – Mandate to innovate – Diversity: People, Geography, Health Status

Innovation in Genomic data sharing – bring data to researchers

SIX types od data wil be collected: Participant-provided Info, mHealth Data, Consent EMR

 

DATA Research CoreVanderbuilt, Verily Broad

  1. pharmacogenomics

Launch start ups cost

  1. Open source
  2. Cloud
  3. developers start ups

PLATFORM

 

GATK – workhorse of genomic data – Launched 4/2016

Partnerships: Amazon, google genomics, microsoft, IBM, Watson, 

 

Announcing: BROAD + Intel Center for Advanced Genomic Data Engineering, Anthony Philippakis, M.D., Ph.D., Chief Data Officer, Broad Institute

Reference Architecture: Design: Single node, small cluster,

 

4:30 p.m. — Closing Remarks

  • Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

 

– See more at: http://www.personalizedmedicinecoalition.org/Conference/November_17_Program#sthash.zpTNQYKd.dpuf

 

#PMConf

SOURCE

http://www.personalizedmedicinecoalition.org/Conference/November_17_Program


LIVE 11/17 8AM – 1:45PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Leaders in Pharmaceutical Business intelligence (LPBI) Group

Covering in Real Time using Social Media this Event on

Personalized Medicine

Aviva Lev-Ari, PhD, RN, Founder LPBI Group & Editor-in-Chief

http://pharmaceuticalintelligence.com

Streaming LIVE @ HARVARD MEDICAL SCHOOL,

Joseph B. Martin Conference Center

@pharma_BI

@AVIVA1950

November 17

#PMConf

 

Joseph B. Martin Conference Center
77 Avenue Louis Pasteur
Boston, MA 02115

7:00 a.m. — Registration and Continental Breakfast

8:00 a.m. — Opening Remarks

  • Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

8:15 a.m. — Fireside Chat

  • Moderator: Meg Tirrell, Reporter, CNBC
  1. How did the the Economics changed
  • Daniel O’Day, CEO, Roche Pharmaceuticals – Joined Roche at 1989
  1. Roche  – 60% of investments goes to Cancer with embedded diagnostics, 20-30% of the market
  2. Hypothesis in the Lab starts an innovation – Phase I, Phase II is extension of Phase I – continue understanding of the Biology of the Disease
  3. Treat only patient that will benefit – PM – transformational benefit
  4. Early stage of discovery – protection of IP – work inside ONE company — less of an issur the protection of IP
  5. Diagnostics area – Roche collaborates with other Pharma
  6. Setting infrastructure for testing
  7. Diagnostics and Pharma are coming together – availability of big data – discover and develop with Foundation Medicine – Deep analysis of Molecular Medicine, decide o better hypothesis, do it in shorter time – 2015 – Commercialize the platform around the Globe, One standard for Clinical Trials – in China hard to move Clinical Trials Data out of China –
  8. Harnessing Global Data in Oncology – Clinical Trials
  9. Data accuracy
  10. Genentech, Foundation Medicine and Roche capabilities – FDA
  11. Comprehensive Genomics side – has needs yet to be developed for Payers to participate
  12. Foundation One – 30% more positive Lung Cancers found vs standard of testing
  13. Over simplification is dangerous, technology/diagnostocs/histology/genomics – sequencing ENHANCES not replaces
  14. Data of Phase III – robust genomics profiling: no diagnostics and wrong diagnostics
  15. In the next five years, Cancer immunotherapy, when and how resistance occur.
  16. Blood based assay – Patient journey  – fine tuning the Science tissue based sample
  17. Biomarkers: Tumor microenvironment
  18. Diagnostics is not rewarded appropriately, genetics, CMS,
  19. Outcome value for TX and Dx
  20. Mission of Roche will not Change with change of Gov’t, public Sector in the US, FDA – requires being faster a respondent,
  21. ” I am optimistic”

Questions from the audience

  • Democratizing access to sequencing data
  • accuracy of test results, Oncologist and PCP ordering genomics tests, value added
  • PM after medicine SOC (biopsy, tissue histology)
  • Reimbursement: Diagnostics vs drugs

8:45 a.m. — Coverage is King: Identifying the Evidence That Leads to Reimbursement

Many innovators in personalized medicine are unclear on the kinds of evidence that inform the coverage and payment decisions of payers. That lack of clarity can have negative financial consequences for personalized medicine companies with products and services that are on the market but not paid for. During this panel, payer representatives will help define the reimbursement landscape for the field by providing examples of the evidence they consider appropriate for coverage and payment. Confirmed panelists include:

  • Moderator:Amy M. Miller, Ph.D., Executive Vice President, Personalized Medicine Coalition
  1. What each of the companies does in PM
  2. Targeted therapeutics: 25% are targeted,
  3. Value of Diagnostics
  • Kristine Bordenave, M.D., Lead Medical Director, Humana
  1. Clinical perspective, how much it cost to patient, clinician, Pharma – both need to be paid,
  2. Population Health, 100% of GDP to go to HealthCare — can’t be
  3. Humana Perspective: How to cover – organized criming: Charges for Testin – several month doen in one day, sharing drugs, expired drugs, repackaged and sold, drugs resold
  4. Independent Research Department: MS, Pharmacists, Statisticians — Looking at the Value of Test in Population context
  5. Large Medicare, Small managed care company, Value-based contracts: working with Pharma – early on at Phase II stage
  6. Testing: genetics, radiographic — 60 gene panel – done by two labs,
  7. Duplication in ordering genetic testing: optometrists, Physical therapist, ordering genetic profiling
  • Matthew Fontana, M.D., Vice President and Chief Medical Officer, Pharmacy, Health Care Service Corporation
  1. WHY REFERE TO US AS PAYERS – BUSINESS MODEL: MULTIPLE CUSTOMERS MEDICAID, BIG PROVIDERS, MANAGED CARE INDUSTRY
  2. Cost and Revenue
  3. FDA is been pushed to ignore the science (DMD), lack of coordination in HealthCare
  4. Pay for diagnostics if not linked to Therapeutics – morbidity
  5. elaboration of Diagnostics
  6. Accuracy of testing – expensive  – misinterpretation
  • Elaine Jeter, M.D., MolDx Medical Director, Palmetto GBA
  1. Access of Patients – 25 of 50 States are participants in MOlDx — NOT New England States
  2. All molecular assays to register for code specificity – to be able to control appropriate coding – Panel matched to unit of service issue between Genome Profiling and assay
  3. Reimbursement – Lung Cancer – Clinical utility  – genomic profiling ONLY IF THE DATA IS IN A REGISTRY — IF PROVED UTILITY AND THE REGISTRY SHOULD BE IN PUBLIC DOMAIN
  4. Analytical minimal standard accepted
  5. Developed Assessment meetings – Labs come to receive guidance  – clinical utility information, as a contractor – Central Office allowed PM vs Lab developing tests – assist Lab – pay for service obtain end points
  6. Assays for Prostate Cancer – innovative – high disease demand, define endpoints
  7. Paying premium for FDA approved genetic testing – onlu 2% of molecular assays — 98% are not FDA approved
  8. 65,000 molecular tests in the market in the Registry only 10,000, every day 2-3 new molecular assay tests are introduced
  9. By statue, no screening covered by Medicare for Genetic testing – congress need to act upon that – change coverage of Medicare. Memogram and colonoscopy, lung X-ray – are by statue – covered by Medicare

Questions from the Audience

  • Why premium paid if FDA approved a test?
  • Screening and early detection

9:45 a.m. — Networking Break

10:15 a.m. — Harvard Business School Case Study Presentation

DNA-editing technologies have been hailed as revolutionary with the possibility to edit out mutations that cause disease.  Yet the CRISPR-Cas system is currently locked in a legal dispute between two great research institutions involving, as one journalist put it, “who owns molecular biology.”  The CRISPR technology in short raises the broader issue of whether these new techniques should be privately owned or placed in the public domain. The technology also raises serious ethical issues. The case study will serve as the point of departure for our discussion of these issues.

  • Leader:Richard Hamermesh, D.B.A., Senior Fellow and Former MBA Class of 1961, Professor of Management Practice, Harvard Business School
  1. Ethical issues in the case
  2. Stacks are very high

11:15 a.m. — Keynote Speaker

  • Introduction:William Chin, M.D., Chief Medical Officer, Executive Vice President, PhRMA
  • Keynote:Victor Dzau, M.D., President, National Academy of Medicine (ex-IOM) – part of NIH
  1. Global Landscape of PM: Integration into HealthCare — Cost effectiveness
  2. Evidence for PM
  3. better health and well being
  4. high value health care
  5. strong science & technology – 150 papers in JAMA ans NAS
  6. Precision Medicine: patient/public engagement, NGS: omics, biomarkers, collection of clinical & research data, integration of omics, EHR
  7. Challenges: Tests & Therapies
  8. efficacy of PM AFTER actually being used in clinical practice
  9. Evidence of PM efficacy for implementation in Practice
  10. Regulatory and Reimbursement for utility
  11. Reward Value vs cost
  12. Aligning Results: 10% incidence reduction vs 50% incidence reduction
  13. Evidence generation:
  14. Modeling could be used to assess the potential economic impact of PM approaches
  15. Final regulatory & Payment Pathwaysand payer approval
  16. Analytic Validity — clinical validity — economic impact analysis– Assess Clinical Utility
  17. Strength of evidence Low to High
  18. investigational experiment
  19. Assess cost effectiveness: initial experimentation — Economic analysis — provisional approval — validation — final approval
  20. Integration with clinical Practice: Clinician Educatuin, integration pathways
  21. Genomic Medicine:guideline and care pathways — Clinical DSS —
  22. Data infrastructure and sharing: EHR (DIGITize) – genomics – GA4GH
  23. PATIENT/PUBLIC ENGAGEMENT – concern of Privacy and Data Ownership – Fear of discrimination  — consent — education of Patients
  24. Future needs: data, National scale learning system, Global collaboration G2GH
  25. Support Data infrastructure
  26. PM – quality, access, cost, improve clinical outcomes, inequality mitigate
  27. PRECISION PUBLIC HEALTH – ZIKA, EBOLA,
  28. GENOMICS and Population Health Action Collaborative
  29. working Groups: Evidence generation

11:45 a.m. — Bag Lunch

12:45 p.m. — Personalizing Care: Strategies for Integrating Personalized Medicine into Health Care

Personalized medicine lacks sufficient literature on how health care providers can integrate personalized medicine into clinical care, which makes it difficult for providers to take advantage of the growing number of personalized medicine products and services now available to them. During this session, panelists who have spearheaded integration efforts will share the strategies they found most useful for speeding the pace of personalized medicine’s adoption in clinical settings. Confirmed panelists include:

  • Moderator:Howard McLeod, Pharm.D., Medical Director, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center
  1. Awareness & education
  2. Patient empowerment
  3. value recognition
  4. IT and Information Management
  5. ensuring Access to Care: Case if Neuropathy than 15 more visits causing 8 other Patients to be pushed in the queue

 

  • Amy Abernethy, M.D., Ph.D., Chief Medical Officer, Chief Scientific Officer, Senior Vice President, Oncology, Flatiron Health
  1. Family and Care givers need to understand as well
  2. More Advocacy in Washington

 

  • Dax Kurbegov, M.D., Physician Vice President, National Oncology Service Line, Catholic Health Initiatives – CHI (103 Hospitals) and DIgnity ospitals – Community system
  1. Provide speed of service
  2. Permeate piece by piece by each institution, economics – problematic IT infrastructure for Genomics is expensive, centralized system needed
  3. broader beyond Oncology
  4. complex Patients with polypharmacy
  5. If physician needs to write a special note for service , patients are lost in the way for testing
  6. as NGS become accessible in labs — CHI provide infrastructure to LINK Patients with Experts and Labs outside the system
  • Lincoln Nadauld, M.D., Ph.D., Executive Director of Precision Genomics, Intermountain Healthcare, UT (22 Hospital 107 physicians – Molecular Tumor Board)
  1. Pilot Project approach implemented in 3 hospitals, built lab, implement by Molecular Tumor Board placed on the report
  2. Barriers: getting drug is difficult – mutation exists, drug exists — How to get the drug ordered, approved and shipped
  3. Patients want to know that their oncology is up to date the care is best, Patient advocate for themselves, Patient empowerment
  4. Barriers to PM – Physician compensated better for next line IV chemo vs Targeted Genomic-based therapy
  5. Tumor Board
  6. Get Genomics EARLY not late – it will max the course of treatment
  7. MOST PATIENT CAN’T TRAVEL FOR CARE because it is expensive
  8. Utility and Value asked by Payors, cost saving need be demonstrated not only efficacy vs SOC – reduce cost must be demonstrated

 

  • Peter H. O’Donnell, M.D., Assistant Professor of Medicine and Associate Director for Clinical Implementation, Center for Personalized Therapeutics, The University of Chicago
  1. Lab Testing, way to long, system for Physician to look at Genomic data,
  2. If Physician is buying in shared decisions with Patient easier
  3. all tests are bundled and results are presented to PCPs – they love that
  4. Drugs fail because Patients do not take them vs Pharmacogenomics – more likely to help Patients

#PMConf

SOURCE

http://www.personalizedmedicinecoalition.org/Conference/November_17_Program